Even with a combined pathology adjusted Manchester score [10] of 20 or higher indicating at least a 20% likelihood of a BRCA1/2 mutation only 5/33 (15%) women with HER2+ breast cancer had a mutation identified. Here, ERBB2 is linked to breast carcinoma.